Tang Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tang Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$1.36M	–	80
2025 Q3	$1.36M	Hold	100,000	–	–	0.05%	147
2025 Q2	$641K	Hold	100,000	–	–	0.03%	180
2025 Q1	$354K	Hold	100,000	–	–	0.02%	189
2024 Q4	$378K	Hold	100,000	–	–	0.03%	174
2024 Q3	$324K	Hold	100,000	–	–	0.02%	138
2024 Q2	$190K	Hold	100,000	–	–	0.02%	125
2024 Q1	$284K	Sell	100,000 -100,000	-50%	-$1.31M	0.03%	97
2023 Q4	$2.94M	Buy	+200,000	New	+$3.07M	0.27%	79
2023 Q3	–	Sell	-100,000	Closed	-$2.16M	–	107
2023 Q2	$2.16M	Hold	100,000	–	–	0.32%	69
2023 Q1	$2.93M	Hold	100,000	–	–	0.44%	57
2022 Q4	$3.69M	Buy	+100,000	New	+$3.55M	0.54%	45

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Tang Capital Management's AMLX Position: Q4 2025 in Review

Tang Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 100,000 shares — an estimated $1.36M sold.

Tang Capital Management first reported a position in AMLX in Q4 2022 and held it in 11 quarters. The position peaked at $3.69M in Q4 2022. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

Tang Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 100,000 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $1.36M.
Tang Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Tang Capital Management's Amylyx Pharmaceuticals position peaked at $3.69M in Q4 2022.
179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.